<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04447274</url>
  </required_header>
  <id_info>
    <org_study_id>UPS and ASPS-IIT-SHR1210</org_study_id>
    <nct_id>NCT04447274</nct_id>
  </id_info>
  <brief_title>A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS</brief_title>
  <official_title>A Single-arm, Open, Prospective, Single-center, Phase Ⅱ Clinical Study of Carilizumab Combined With Apatinib in theTtreatment of Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma and Alveolar Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Single-arm, Open, Prospective, Single-center, Phase Ⅱ Clinical Study ,Target
      population is Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma (UPS) and
      Alveolar Soft Tissue Sarcoma (ASPS) .

      The purpose of this study was to evaluate the safety and efficacy of combination of
      Camrelizumab and Apatinib in the treatment of unresectable UPS and ASPS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, eligible subject to accept study treatment. Camrelizumab combined with
      apatinib is a treatment cycle every 2 weeks
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free rate at 12 weeks (PFR 12weeks)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The RECIST 1.1 standard was used to evaluate the disease progression and the 12 week progression free rate was calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>6.5 months</time_frame>
    <description>It is defined as the proportion of patients whose tumors shrink to a predetermined size and maintain a minimum time limit. It includes the cases of CR and PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>6.5 months</time_frame>
    <description>Refers to the date from the beginning of treatment to the first occurrence of disease progression or death caused by any reason, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response（DOR)</measure>
    <time_frame>6.5 months</time_frame>
    <description>Time from the first assessment of Cr or PR to the first assessment of PD or death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Camrelizumab and Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab and Apatinib</intervention_name>
    <description>Subject will receive SHR-1210 200mg every 2 weeks, with intravenous drip Apatinib 425 mg, oral, 5 consecutive days, 2 days off,each 14 day of a cycles</description>
    <arm_group_label>Camrelizumab and Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects &gt;/= 16 years of age at the time of Informed Consent,male or female;

          2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;

          3. Life expectancy of at least three months;

          4. Advanced undifferentiated pleomorphic sarcoma (UPS) confirmed by histopathology,
             patients who have failed in the first-line treatment and have progressed for 6 months;
             advanced acinar soft tissue sarcoma (ASPS) confirmed by histopathology, patients who
             have not been treated or who have failed in the first-line anti vascular drug
             treatment and progressed within 6 months;

          5. Subjects enrolled must have measurable lesion(s) according to the RECIST 1.1 standard
             (the CT scan length of the tumor lesion &gt; 10 mm;

          6. All acute toxic reactions caused by previous anti-tumor treatment were relieved to 0-1
             level before enrollment (according to NCI CTCAE 5.03) Version) or to the level
             specified in the inclusion / exclusion criteria (except for the toxicity that
             researchers think does not pose a safety risk to subjects, such as hair loss); if
             subjects undergo major surgery, they must have fully recovered from complications
             before starting treatment;

          7. The main organ function is normal. All baseline laboratory requirements will be
             assessed and should be obtained within -14 days of randomization. Screening laboratory
             values must meet the following criteria.

               1. Hemoglobin ≥ 8.0 g/dL (90 g/L)

               2. Absolute neutrophil count ≥ 1.5× 109/L

               3. Platelets ≥ 80× 109/L

               4. Total bilirubin (TBIL) &lt; 1.5 × upper limit of normal (ULN)

               5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 2.5 × upper
                  limit of normal(ULN);but &lt; 5uln in patients with liver metastasis, alkaline
                  phosphatase &lt; 5 × ULN

               6. Serum creatinine ≤ 1× ULN or creatinine clearance &gt; 45 mL/minute (using
                  Cockcroft/Gault formula);

          8. Women of childbearing age must have taken reliable contraceptive measures or carried
             out pregnancy test (serum or urine) within 7 days before entering the group, and the
             result is negative, and they are willing to use appropriate contraceptive methods
             during the test and 60 days after the last administration of test drugs. For men, they
             must agree to use appropriate methods of contraception or have undergone surgical
             sterilization during the trial period and within 120 days after the last
             administration of the trial drug;

          9. Subjects should be voluntarily participate in clinical studies and informed consent
             should be signed.

        Exclusion Criteria:

          1. Known active central nervous system (CNS) metastasis and / or cancerous meningitis.
             Subjects who had previously received brain metastases may participate as long as they
             are stable and meet the following criteria: there is no evidence of imaging progress
             for at least four weeks prior to the first dose of trial treatment, and any
             neurological symptoms have returned to baseline, there is no evidence of new or
             expanded brain metastases, and steroids are not used for at least seven days prior to
             the trial treatment. This exception does not include cancerous meningitis, regardless
             of its clinical stability;

          2. Immunosuppressive drugs were used within 14 days before the first use of carrizumab,
             excluding nasal spray and inhaled corticosteroids or systemic steroids with
             physiological dose (i.e. no more than 10 mg / day of prednisolone or other
             corticosteroids with physiological dose of the same drug); 3. Previously received the
             following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs for another
             stimulation or synergistic inhibition of T cell receptor (for example, CTLA-4, OX-40,
             CD137); 4. Uncontrollable hypertension (systolic blood pressure ≥ 140 mmHg or
             diastolic blood pressure ≥ 90 mmHg, despite systematic medication); 5. Severe
             cardiovascular disease: myocardial ischemia or myocardial infarction above grade II,
             poor control of arrhythmia (including QTc interval ≥ 450 ms for men and 470 MS for
             women); cardiac insufficiency of grade III-IV (according to NYHA classification of New
             York Heart Association, see Annex 3), or left ventricular ejection fraction (LVEF) &lt;
             50% indicated by color Doppler echocardiography; 6. Patients with any active
             autoimmune disease or history of autoimmune disease (including but not limited to:
             autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis,
             vasculitis, nephritis, hyperthyroidism, hypothyroidism) shall not be included; 7. The
             subjects received systematic treatment such as bronchodilator, and the asthma control
             was not satisfactory and could not be included (the asthma in childhood has been
             completely relieved, and the adult can be included without any intervention); 8.
             Routine urine test indicated that urine protein was ≥ 1.0g, or 24-hour urine protein
             was ≥ 1.0g; 9. Abnormal coagulation (INR &gt; 1.5 ULN or prothrombin time (PT) &gt; ULN + 4
             seconds or APTT &gt; 1.5 ULN), with bleeding tendency or undergoing thrombolysis or
             anticoagulation treatment; Note: on the premise that the international standard ratio
             of prothrombin time (INR) is less than or equal to 1.5, it is allowed to use low-dose
             heparin (6000-12000 u daily for adults) or aspirin (less than or equal to 100 mg
             daily) for prevention purposes; 10. Severe infection (such as intravenous drip of
             antibiotics, antifungal drugs or antiviral drugs) occurred within 4 weeks before the
             first administration, or fever of unknown cause occurred during screening / before the
             first administration &gt; 38.5 ° C; 11. Serious arteriovenous thrombotic events occurred
             in the first 12 months, such as cerebrovascular accident (including temporary ischemic
             attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary
             embolism; 12. In the first 4 weeks of the group, they had undergone major surgery or
             had severe traumatic injury, fracture or ulcer; 13. Human immunodeficiency virus (HIV)
             infection or known acquired immunodeficiency syndrome (AIDS), active tuberculosis,
             active hepatitis B (HBV DNA ≥ 500 IU / ml), hepatitis C (HCV antibody positive, and
             HCV-RNA higher than the detection limit of the analysis method) or co infection with
             hepatitis B and C; 14. Patients with a clear history of allergy may be potentially
             allergic or intolerant to the biological agents of apatinib and carrizumab; 15. There
             are obvious factors affecting the absorption of oral drugs, such as inability to
             swallow, chronic diarrhea and intestinal obstruction. Or there were cavity organ sinus
             or perforation within 6 months; 16. Those who have a history of abuse of psychotropic
             substances and are unable to give up or have mental disorders; 17. Increase the risk
             associated with participating in the study or study drug, and other circumstances
             that, in the judgment of the investigator, may result in the patient not being
             eligible for inclusion in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yihebali Chi, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yihebali Chi, doctor</last_name>
    <phone>13911075626</phone>
    <email>yihebalichi6@126.com</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>June 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>yihebali chi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Camrelizumab</keyword>
  <keyword>Apatinib</keyword>
  <keyword>UPS</keyword>
  <keyword>ASPS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

